• Fernanda RazeraEmail author
  • Renan Rangel Bonamigo


Paraneoplastic dermatoses are skin lesions caused by the presence of malignant tumors, but unrelated to the direct action of the tumor and its skin metastases. Dermatologic lesions are the second most common form of paraneoplastic syndrome, immediately after endocrine manifestations. This chapter covers the main paraneoplastic dermatoses cited in the literature. Among them are acanthosis nigricans maligna, tripe palms, acquired ichthyosis, erythema gyratum repens, Bazex syndrome, acquired hypertrichosis lanuginosa, necrolytic migratory erythema, erythema gyratum repens, Leser–Trélat sign, paraneoplastic pemphigus, paraneoplastic neutrophilic dermatoses, multicentric reticulohistiocytosis, and necrobiotic xanthogranuloma. Although they are rare they are very important lesions in the practice of dermatology, since in many cases paraneoplastic dermatosis is the first manifestation of the neoplasia, enabling an earlier diagnosis of the tumor, improving its prognosis, and also, because of the parallel course with the neoplasia, helping to monitor its recurrence.


Paraneoplastic syndrome Paraneoplastic dermatoses Acanthosis Tripe palms Ichthyosis Erythema gyratum repens Bazex Hypertrichosis lanuginosa Necrolytic migratory erythema Pemphigus Leser–Trélat Neutrophilic dermatoses Multicentric reticulohistiocytosis Necrobiotic xanthogranuloma 




Thickening of the spinous layer. It is a type of epidermal hyperplasia.


Clinical condition characterized by erythematous to violaceous papulosquamous plaques arise over accrual areas.

Erythema gyratum repens

Disorder characterized by the presence of polycyclic, serpiginous erythema with scaling on its border, rapidly progressive, producing ring-shaped erythematous, concentric figures similar to a wood surface. It is highly associated with neoplasias.


A condition characterized by generalized erythema and scaling, often associated with pruritus and systemic symptoms


A benign tumor-like malformation composed of an abnormal mixture of mature cells and tissues found in areas of the body where growth occurs. It is considered a developmental error and can occur at a number of sites. Example: hemangiomas, melanocytic nevi.


Increase in density and length of the hair accepted limits of normal for age, sex, or race.


Prolonged retention of the stratum corneum, leading to the formation of fishlike scales.


Low molecular weight molecules (cytokines), important intercellular messengers, produced by leukocytes, which preferably exert their effect in other white blood cells.


State of having multiple benign tumor of smooth muscle (leiomyomas).

Leser–Trélat sign

Sudden increase in the quantity and rapid growth in size of seborrheic keratoses.

Multiple endocrine neoplasias

Rare, inherited genetic mutational disorders whereby several endocrine glands develop benign or malignant tumors or grow excessively without forming tumors. A single gene responsible for type 1 disease has been identified. Abnormalities in a different gene have been identified in persons with types 2A and 2B disease.

Necrobiotic xanthogranuloma

A disease caused by a granulomatous inflammation that results in the presence of plaques and firm, yellowish nodules, particularly in the face.


Describes processes occurring in cell necrosis and tissue detachment.


Palmar thickening with marked palmar ridges and grooves, which exaggerate the dermatoglyphs (digital print) giving it a rough, velvety appearance.

Paraneoplastic disease

Clinical or biochemical alterations associated with malignant neoplasias that are not directly related to the invasion of the primary tumor or its metastases.


Descriptive term that combines atrophy, telangiectasia, and hyper- or hypopigmentation that may occur in different clinical situations.

Reticulohistiocytosis, multicentric

Systemic granulomatous disease of unknown cause. Papulonodular skin lesions containing a proliferation of true histiocytes (macrophages) are associated with arthritis.


  1. 1.
    Chung VQ, Moschella SL, Zembowicz A, et al. Clinical and pathologic findings of paraneoplastic dermatoses. J Am Acad Dermatol. 2006;54(5):745–62.CrossRefPubMedGoogle Scholar
  2. 2.
    Stedman TL. Dicionário médico. 25th ed. Rio de Janeiro: Guanabara Koogan; 1996. p. 945.Google Scholar
  3. 3.
    Silva JA, Igreja ACDSM, Freitas AF, et al. Paraneoplastic cutaneous manifestations: concepts and updates. An Bras Dermatol. 2013;88(1):9–22.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Pipkin CA, Lio PA. Cutaneous manifestations of internal malignancies: an overview. Dermatol Clin. 2008;26:1–15.CrossRefPubMedGoogle Scholar
  5. 5.
    Curth HO. Skin lesions and internal carcinoma. In: Andrade R, editor. Cancer of the skin: biology, diagnosis, management. Philadelphia: Saunders; 1976.Google Scholar
  6. 6.
    Koyama S, Ikeda K, Sato M, Shibahara K, Yuhara K, et al. Transforming growth factor-alpha (TGFα)-producing gastric carcinoma with acanthosis nigricans: an endocrine effect of TGFα in the pathogenesis of cutaneous paraneoplastic syndrome and epithelial hyperplasia of the esophagus. J Gastroenterol. 1997;32:71–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Krawczyk M, Mykała-Cieśla J, Kołodziej-Jaskuła A. Acanthosis nigricans as a paraneoplastic syndrome. Case reports and review of literature. Polskie Arch Med Wewn. 2009;119:180–3.Google Scholar
  8. 8.
    Yeh JSM, Munn SE, Plunkett TA, Harper PG, Hopster DJ, et al. Coexistence of acanthosis nigricans and the sign of Leser-Trelat in a patient with gastric adenocarcinoma: a case report and literature review. J Am Acad Dermatol. 2000;42(3):57–62.Google Scholar
  9. 9.
    Pentenero M, Carrozzo M, Pagano M, Gandolfo S. Oral acanthosis nigricans, tripe palms and sign of Leser-Trélat in a patient with gastric adenocarcinoma. Int J Dermatol. 2004;43:530–2.CrossRefPubMedGoogle Scholar
  10. 10.
    Brinca A, Cardoso JC, Brites MM, Tellechea O, Figueiredo A. Florid cutaneous papillomatosis and acanthosis nigricans maligna revealing gastric adenocarcinoma. An Bras Dermatol. 2011;86:573–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Zhang N, Qian Y, Feng AP. Acanthosis nigricans, tripe palms, and sign of Leser-Trélat in a patient with gastric adenocarcinoma: case report and literature review in China. Int J Dermatol. 2015;54:338–42.CrossRefPubMedGoogle Scholar
  12. 12.
    Lo WL, Wong CK. Tripe palms: a significant cutaneous sign of internal malignancy. Dermatology. 1992;185:151–3.CrossRefPubMedGoogle Scholar
  13. 13.
    Cohen PR, Grossman ME, Almeida L, Kurzrock R. Tripe palms and malignancy. J Clin Oncol. 1989;7:669–78.CrossRefPubMedGoogle Scholar
  14. 14.
    Chosidow O, Becherel PA, Piette JC, Arock M, Debre P, Frances C. Tripe palms associated with systemic mastocytosis: the role of transforming growth factor-a and efficacy of interferon-alfa. Br J Dermatol. 1998;138:698–703.CrossRefPubMedGoogle Scholar
  15. 15.
    Schwartz RA. Sign of Leser-Trélat. J Am Acad Dermatol. 1996;35:88–95.CrossRefPubMedGoogle Scholar
  16. 16.
    Turan E, Gurel MS, Erdemir AT. Leser-Trélat sign: a paraneoplastic process? Cutis. 2014;94:E14–5.PubMedGoogle Scholar
  17. 17.
    Safa G, Darrieux L. Leser-Trélat sign without internal malignancy. Case Rep Oncol. 2011;4:175–7.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Fink AM, Filz D, Krajnik G, Jurecka W, Ludwig H, Steiner A. Seborrhoeic keratoses in patients with internal malignancies: a case-control study with prospective accrual of patients. J Eur Acad Dermatol Venereol. 2009;23:1316–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Aram H. Acquired ichthyosis and related conditions. Int J Dermatol. 1984;23(7):458–61.CrossRefPubMedGoogle Scholar
  20. 20.
    Cooper MF, Wilson PD, Hartop PJ, et al. Acquired ichthyosis and impaired dermal lipogenesis in Hodgkin’s disease. Br J Dermatol. 1980;102(6):689–93.CrossRefPubMedGoogle Scholar
  21. 21.
    Moore RL, Devere TS. Epidermal manifestations of internal malignancy. Dermatol Clin. 2008;26:17–29.CrossRefPubMedGoogle Scholar
  22. 22.
    Bolognia JL, Brewer YP, Cooper DL. Bazex syndrome (acrokeratosis paraneoplastica). An analytic review. Medicine (Baltimore). 1991;70(4):269–80.CrossRefGoogle Scholar
  23. 23.
    Bolognia JL. Bazex syndrome: acrokeratosis paraneoplastica. Semin Dermatol. 1995;14(2):84–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Valdivielso M, Longo I, Suarez R, et al. Acrokeratosis paraneoplastica: Bazex syndrome. J Eur Acad Dermatol Venereol. 2005;19(3):340–4.CrossRefPubMedGoogle Scholar
  25. 25.
    Eubanks LE, McBurney E, Reed R. Erythema gyratum repens. Am J Med Sci. 2001;321(5):302–5.CrossRefPubMedGoogle Scholar
  26. 26.
    Boyd AS, Neldner KH, Menter A. Erythema gyratum repens: a paraneoplastic eruption. J Am Acad Dermatol. 1992;26(5 Pt 1):757–62.CrossRefPubMedGoogle Scholar
  27. 27.
    Appell ML, Ward WQ, Tyring SK. Erythema gyratum repens. A cutaneous marker of malignancy. Cancer. 1988;62(3):548–50.CrossRefPubMedGoogle Scholar
  28. 28.
    Bakos N, Krasznai G, Bégány Á. Erythema gyratum repens an immunologic paraneoplastic dermatosis. Pathol Oncol Res. 1997;3:59–61.CrossRefPubMedGoogle Scholar
  29. 29.
    Kovacs RK, Korom I, Dobozy A, et al. Necrolytic migratory erythema. J Cutan Pathol. 2006;33(3):242–5.CrossRefPubMedGoogle Scholar
  30. 30.
    Chastain MA. The glucagonoma syndrome: a review of its features and discussion of new perspectives. Am J Med Sci. 2001;321(5):306–20.CrossRefPubMedGoogle Scholar
  31. 31.
    Wermers RA, Fatourechi V, Wynne AG, et al. The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine. 1996;75:53–63.CrossRefPubMedGoogle Scholar
  32. 32.
    Beek AP, Haas ERM, Vloten WA, Lips CJM, Roijers JFM, Canninga-van Dijk MR. The glucagonoma syndrome and necrolytic migratory erythema: a clinical review. Eur J Endocrinol. 2004;151:531–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001;357:96–100.CrossRefPubMedGoogle Scholar
  34. 34.
    Wakata N, Kurihara T, Saito E, Kinoshita M. Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol. 2002;41:729–34.CrossRefPubMedGoogle Scholar
  35. 35.
    Ramos-E-Silva M, Carvalho JC, Carneiro SC. Cutaneous paraneoplasia. Clin Dermatol. 2011;29:541–7.Google Scholar
  36. 36.
    Sparsa A, Liozon E, Herrmann F, Ly K, Lebrun V, et al. Routine vs extensive malignancy search for adult dermatomyositis and polymyositis: a study of 40 patients. Arch Dermatol. 2002 Jul;138(7):885–90.CrossRefPubMedGoogle Scholar
  37. 37.
    Wang J, Guo G, Chen G, Wu B, Lu L, Bao L. Meta-analysis of the association of dermatomyositis and polymyositis with cancer. Br J Dermatol. 2013;169:838–47.CrossRefPubMedGoogle Scholar
  38. 38.
    Ohzono A, Sogame R, Li X, Teye K, Tsuchisaka A, Numata S, Koga H, Kawakami T, Tsuruta D, Ishii N, Hashimoto T. Clinical and immunologic findings in 104 cases of paraneoplastic pemphigus. Br J Dermatol. 2015;173:1447–52.CrossRefPubMedGoogle Scholar
  39. 39.
    Yong AA, Tey HL. Paraneoplastic pemphigus. Aust J Dermatol. 2013;54:241–50.CrossRefGoogle Scholar
  40. 40.
    Nguyen VT, Ndoye A, Bassler KD, et al. Classification, clinical manifestations, and immunopathologic mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: a reappraisal of paraneoplastic pemphigus. Arch Dermatol. 2001;137:193–206.PubMedGoogle Scholar
  41. 41.
    Porro AM, de Caetano L VN, de SN ML, MMS E. Nonclassical forms of pemphigus: pemphigus herpetiformis, IgA pemphigus, paraneoplastic pemphigus and IgG/IgA pemphigus. An Bras Dermatol. 2014;89(1):96–117.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Anhalt GJ. Paraneoplastic pemphigus. J Invest Dermatol Symp Proc. 2004;9:29–33.CrossRefGoogle Scholar
  43. 43.
    Sehga VN, Srivastava G. Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome. Int J Dermatol. 2009;48:162–9.CrossRefGoogle Scholar
  44. 44.
    Anhalt GJ, Kim SC, Stanley JR, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med. 1990;323:1729–35.CrossRefPubMedGoogle Scholar
  45. 45.
    Czernik A, Camilleri M, Pittelkow MR, Grando SA. Paraneoplastic autoimmune multiorgan syndrome: 20 years after. Int J Dermatol. 2011;50:905–14.CrossRefPubMedGoogle Scholar
  46. 46.
    Leger S, Picard D, Ingen-Housz-Oro S, Arnault JP, et al. Prognostic factors of paraneoplastic pemphigus. Arch Dermatol. 2012;148(10):1165–72.CrossRefPubMedGoogle Scholar
  47. 47.
    Fitzgerald RL, McBurney EI, Nesbitt LT Jr. Sweet’s syndrome. Int J Dermatol. 1996;35:9–15.CrossRefPubMedGoogle Scholar
  48. 48.
    Villarreal-Villarreal CD, et al. Sweet syndrome: a review and update. Actas Dermosifiliogr. 2016. In press.
  49. 49.
    Cohen PR, Kurzrock R. Sweet’s syndrome and cancer. Clin Dermatol. 1993;11:149–57.CrossRefPubMedGoogle Scholar
  50. 50.
    Cohen PR, Talpaz M, Kurzrock R. Malignancy-associated Sweet’s syndrome: review of the world literature. J Clin Oncol. 1988;6:1887–97.CrossRefPubMedGoogle Scholar
  51. 51.
    Rochet NM, Chavan RN, Capel MA, Wada DA, Gibson LE. Sweet syndrome: clinical presentation, associations, and response to treatment in 77 patients. J Am Acad Dermatol. 2013;69:557–64.CrossRefPubMedGoogle Scholar
  52. 52.
    Cohen PR, Kurzrock R. Sweet’s syndrome revisited: a review of disease concepts. Int J Dermatol. 2003;42:761–78.CrossRefPubMedGoogle Scholar
  53. 53.
    Bennett ML, Jackson JM, Jorizzo JL, Fleischer AB, White WL, Callen JP. Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine. 2000;79:37–46.CrossRefPubMedGoogle Scholar
  54. 54.
    Duguid CM, O’loughlin S, Otridge B, Powell FC. Paraneoplastic pyoderma gangrenosum. Australas J Dermatol. 1993;34:17–22.CrossRefPubMedGoogle Scholar
  55. 55.
    Luz FB, Gaspar TAP, Kalil-Gaspar N, Ramos-e-Silva M. Multicentric reticulohistiocytosis. J Eur Acad Dermatol Venereol. 2001;15:524–31.CrossRefPubMedGoogle Scholar
  56. 56.
    Snow JL, Muller AS. Malignancy-associated multicentric reticulohistiocytosis: a clinical, histologic and immunophenotypic study. Br J Dermatol. 1995;133:71–6.CrossRefPubMedGoogle Scholar
  57. 57.
    Spicknall KE, Mehregan DA. Necrobiotic xanthogranuloma. Int J Dermatol. 2009;48:1–10.CrossRefPubMedGoogle Scholar
  58. 58.
    Kossard S, Winkelmann RK. Necrobiotic xanthogranuloma with paraproteinemia. J Am Acad Dermatol. 1980;3:257–70.CrossRefPubMedGoogle Scholar
  59. 59.
    Ugurlu S, Bartley GB, Gibson LE. Necrobiotic xanthogranuloma: long-term outcome of ocular and systemic involvement. Am J Ophthalmol. 2000;129:651–7.CrossRefPubMedGoogle Scholar
  60. 60.
    Mehregan DA, Winkelmann RK. Necrobiotic xanthogranuloma. Arch Dermatol. 1992;128:94–100.CrossRefPubMedGoogle Scholar
  61. 61.
    Wood AJ, Wagner MVU, Abbott JJ, Gibson LE. Necrobiotic xanthogranuloma a review of 17 cases with emphasis on clinical and pathologic correlation. Arch Dermatol. 2009;145(3):279–84.CrossRefPubMedGoogle Scholar
  62. 62.
    Sindhuphak W, Vibhagool A. Acquired hypertrichosis lanuginosa. Int J Dermatol. 1982;21:599–601.CrossRefPubMedGoogle Scholar
  63. 63.
    Slee PHTJ, Waal RIF, Schagen van Leeuwen JH, Tupker RA, Timmer R, Seldenrijk CA, van Steensel MAM. Paraneoplastic hypertrichosis lanuginosa acquisita: uncommon or overlooked? Br J Dermatol. 2007;157:1087–92.CrossRefPubMedGoogle Scholar
  64. 64.
    Hegedus SI, Schorr WF. Acquired hypertrichosis lanuginose and malignancy. A clinical review and histopathologic evaluation with special attention to the “mantle” hair of Pinkus. Arch Dermatol. 1972;106:84–8.CrossRefPubMedGoogle Scholar
  65. 65.
    Weisshaar E, Weiss M, Mettang T, Yosipovitch G, Zylicz Z. Paraneoplastic itch: an expert position statement from the Special Interest Group (SIG) of the International Forum on the Study of Itch (IFSI). Acta Derm Venereol. 2015;95:261–5.CrossRefPubMedGoogle Scholar
  66. 66.
    Kilic A, Gul U, Soylu S. Skin findings in internal malignant diseases. Int J Dermatol. 2007;46:1055–60.CrossRefPubMedGoogle Scholar
  67. 67.
    Yosipovitch G. Chronic pruritus: a paraneoplastic sign. Dermatol Ther. 2010;23:590–6.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Weisshaar E, Szepietowski JC, Darsow U, Misery L, Wallengren J, et al. European guideline on chronic pruritus. Acta Derm Venereol. 2012;92:563–81.CrossRefPubMedGoogle Scholar
  69. 69.
    Fett N, Haynes K, Propert KJ, Margolis DJ. Five-year malignancy incidence in patients with chronic pruritus: a population-based cohort study aimed at limiting unnecessary screening practices. J Am Acad Dermatol. 2014;70:651–8.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Chiang HC, Huang V, Cornelius LA. Cancer and itch. Semin Cutan Med Surg. 2011;30:107–12.CrossRefPubMedGoogle Scholar
  71. 71.
    Johannesdottir SA, Farkas DK, Vinding GR, Pedersen L, Lamberg A, Sorensen HT, et al. Cancer incidence among patients with a hospital diagnosis of pruritus: a nationwide Danish cohort study. Br J Dermatol. 2014;171:839–46.CrossRefPubMedGoogle Scholar
  72. 72.
    Singer EM, Shin DB, Nattkemper LA, Benoit BM, Klein RS, Didigu CA, et al. IL-31 is produced by the malignant T-cell population in cutaneous T-cell lymphoma and correlates with CTCL pruritus. J Invest Dermatol. 2013;133:2783–27.CrossRefPubMedGoogle Scholar
  73. 73.
    Akhyani M, Ghodsi ZS, Toosi S, Dabbaghian H. Erythroderma: a clinical study of 97 cases. BMC Dermatol. 2005;5:5.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Li J, Zheng HY. Erythroderma: a clinical and prognostic study. Dermatology. 2012;225:154–62.CrossRefPubMedGoogle Scholar
  75. 75.
    Sigurdsson V, Toonstra J, Hezemans-Boer M, Van Vloten WA. Erythroderma. A clinical and follow-up study of 102 patients, with special emphasis on survival. J Am Acad Dermatol. 1996;35:53–7.CrossRefPubMedGoogle Scholar
  76. 76.
    Kurzrock R, Cohen PR. Mucocutaneous paraneoplastic manifestations of hematologic malignancies. Am J Med. 1995;99(2):207–16.CrossRefPubMedGoogle Scholar
  77. 77.
    Rothe MJ, Bialy TL, Grant-Kels JM. Erythroderma. Dermatol Clin. 2000;18:405–15.CrossRefPubMedGoogle Scholar
  78. 78.
    Boyce S, Harper J. Paraneoplastic dermatoses. Dermatol Clin. 2002;20:523–32.CrossRefPubMedGoogle Scholar
  79. 79.
    Reyes MA, Eisen DB. Inherited syndromes. Dermatol Ther. 2010;23:606–42.CrossRefPubMedGoogle Scholar
  80. 80.
    Thiers BH, Sahn RE, Callen JP. Cutaneous manifestations of internal malignancy. CA Cancer J Clin. 2009;59:73–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2018

Authors and Affiliations

  1. 1.Private officePorto AlegreBrazil
  2. 2.Dermatology Service, Hospital de Clínicas de Porto Alegre (HCPA), Federal University of Rio Grande do Sul (UFRGS)Porto AlegreBrazil
  3. 3.Sanitary Dermatology Service of the Department of Health of Rio Grande do Sul State (ADS-SES)Porto AlegreBrazil
  4. 4.Graduate Pathology Program of Federal University of Health Sciences of Porto AlegrePorto AlegreBrazil

Personalised recommendations